VOLGA, EV-304, and More Practice-Changing Trials in MIBC

A roundtable moderated by Karine Tawagi, MD, of the University of Illinois, featured discussion on the treatment landscape of muscle invasive and non-muscle invasive bladder cancer.
Panelists Petros Grivas, MD, PhD, of Fred Hutchinson Cancer Center, and Vadim Koshkin, MD, of the University of California, San Francisco discussed some of the latest practice-changing trials in the treatment landscape, as well as the potential of bladder-sparing treatment approaches and the use of ctDNA.

In the second part of this roundtable, new trials including VOLGA and EV-304 are analyzed.

View the third segment of this roundtable: The NIAGARA Trial, Cisplatin Regimens, and the Potential of Durvalumab With Gem/Cis for MIBC